Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.

Watada H, Kaneko S, Komatsu M, Agner BR, Nishida T, Ranthe M, Nakamura J

Diabetes, obesity & metabolism17 Sept 2019Cited by 26 (Europe PMC)

PMID31423685PMCIDPMC6900157DOI10.1111/dom.13859PepBankPUB-31423685

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes uncontrolled on basal or pre-mix insulin, IDegLira lowered HbA1c more than degludec at 26 weeks.
In plain wordsIn Japanese adults with type 2 diabetes, insulin plus liraglutide lowered HbA1c more than insulin alone.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline at 26 weeks
Study
n = 210
Comparator
Insulin degludec (up to 50 U)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
IDegLira up to 50 dose steps · 26 weeksAs given in this study (human).
Measurements
Estimated treatment difference in HbA1c
−13.98 mmol/Mol
IDegLira vs degludec
HbA1c change
−21.3 mmol/Mol
IDegLira
HbA1c change
−7.1 mmol/Mol
degludec
Source sentences
Summary
IDegLira was superior to degludec with respect to change from baseline in HbA1c: estimated treatment difference (ETD) (95% confidence interval), -13.98 mmol/Mol (-16.41; -11.55); P < 0.0001.
3 context sentences(design, population, supporting numbers)
Summary · context
The change in mean HbA1c was from 70.6 by -21.3 mmol/Mol with IDegLira and from 70.1 by -7.1 mmol/Mol with degludec.
Summary · context
In this 26-week, double-blind, multicentre, treat-to-target trial, Japanese individuals with T2D that was uncontrolled with basal or pre-mix insulin (20-50 units) were randomized (1:1) to receive IDegLira or degludec, both with metformin.
Summary · context
The maximum dose was 50 dose steps (IDegLira) or 50 units (degludec).
Report a problemFND-3142368501
02HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, body weight changed by -0.7 kg with IDegLira and 0.7 kg with degludec.
In plain wordsIn Japanese adults with type 2 diabetes, weight fell slightly with insulin plus liraglutide and rose slightly with insulin alone.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 210
Comparator
Insulin degludec (up to 50 U)
Outcome group
Body weight · Metabolic and weight
Studied dose
IDegLira up to 50 dose steps · 26 weeksAs given in this study (human).
Measurements
Body weight change
−0.7 kg
IDegLira
Body weight change
0.7 kg
degludec
Estimated treatment difference
−1.41 kg
IDegLira vs degludec
Source sentences
Summary
Mean change in body weight was -0.7 kg with IDegLira and 0.7 kg with degludec: ETD (95% CI) -1.41 kg (-2.26; -0.56); P = 0.0012.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, multicentre, treat-to-target trial, Japanese individuals with T2D that was uncontrolled with basal or pre-mix insulin (20-50 units) were randomized (1:1) to receive IDegLira or degludec, both with metformin.
Summary · context
The maximum dose was 50 dose steps (IDegLira) or 50 units (degludec).
Report a problemFND-3142368502
03HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes, mean daily total insulin dose at week 26 was significantly lower with IDegLira than with degludec.
In plain wordsIn Japanese adults with type 2 diabetes, people on insulin plus liraglutide needed less insulin per day than people on insulin alone.
Peptide
Liraglutide
Outcome
DecreaseMean daily total insulin dose
Study
n = 210
Comparator
Insulin degludec (up to 50 U)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
IDegLira up to 50 dose steps · 26 weeksAs given in this study (human).
Measurements
Mean daily total insulin dose
37.6 U
IDegLira
Mean daily total insulin dose
41.2 U
degludec
Source sentences
Summary
Mean daily total insulin dose was significantly lower with IDegLira (37.6 U) as compared to that with degludec (41.2 U) at Week 26.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, multicentre, treat-to-target trial, Japanese individuals with T2D that was uncontrolled with basal or pre-mix insulin (20-50 units) were randomized (1:1) to receive IDegLira or degludec, both with metformin.
Summary · context
The maximum dose was 50 dose steps (IDegLira) or 50 units (degludec).
Report a problemFND-3142368503
04HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, overall rates of severe or confirmed hypoglycaemia were comparable between IDegLira and degludec.
In plain wordsIn Japanese adults with type 2 diabetes, low blood sugar events were about equally frequent with insulin plus liraglutide and insulin alone.
Peptide
Liraglutide
Outcome
No significant changeSevere or blood glucose-confirmed hypoglycaemia
Study
n = 210
Comparator
Insulin degludec (up to 50 U)
Outcome group
Adverse events · Metabolic and weight
Studied dose
IDegLira up to 50 dose steps · 26 weeksAs given in this study (human).
Source sentences
Summary
Overall rates of severe or blood glucose-confirmed hypoglycaemia and adverse events were comparable between treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, multicentre, treat-to-target trial, Japanese individuals with T2D that was uncontrolled with basal or pre-mix insulin (20-50 units) were randomized (1:1) to receive IDegLira or degludec, both with metformin.
Summary · context
The maximum dose was 50 dose steps (IDegLira) or 50 units (degludec).
Report a problemFND-3142368504
05HumanRandomized controlled trialSafety outcome
In Japanese adults with type 2 diabetes, overall adverse event rates were comparable between IDegLira and degludec.
In plain wordsIn Japanese adults with type 2 diabetes, side effects were about equally frequent with insulin plus liraglutide and insulin alone.
Peptide
Liraglutide
Outcome
No significant changeOverall adverse events
Study
n = 210
Comparator
Insulin degludec (up to 50 U)
Outcome group
Adverse events · Whole body
Studied dose
IDegLira up to 50 dose steps · 26 weeksAs given in this study (human).
Source sentences
Summary
Overall rates of severe or blood glucose-confirmed hypoglycaemia and adverse events were comparable between treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, multicentre, treat-to-target trial, Japanese individuals with T2D that was uncontrolled with basal or pre-mix insulin (20-50 units) were randomized (1:1) to receive IDegLira or degludec, both with metformin.
Summary · context
The maximum dose was 50 dose steps (IDegLira) or 50 units (degludec).
Report a problemFND-3142368505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02911948

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Novo Nordisk A/Sn = 21021 Sept 2016 to 22 Nov 2017

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 9 Apr 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.